{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,10]],"date-time":"2026-09-10T03:33:56Z","timestamp":1789011236574,"version":"build-2803163510"},"reference-count":22,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,8,1]],"date-time":"2025-08-01T00:00:00Z","timestamp":1754006400000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","msard-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Multiple Sclerosis and Related Disorders"],"published-print":{"date-parts":[[2025,8]]},"DOI":"10.1016\/j.msard.2025.106542","type":"journal-article","created":{"date-parts":[[2025,5,24]],"date-time":"2025-05-24T18:41:28Z","timestamp":1748112088000},"page":"106542","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":3,"special_numbering":"C","title":["Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients"],"prefix":"10.1016","volume":"100","author":[{"given":"Hazal Ceren","family":"Manazo\u011flu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclce","family":"\u0130\u015fkan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tuncay","family":"G\u00fcnd\u00fcz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ahmed Serkan","family":"Emekli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fcl\u015fen","family":"Akman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Burcu","family":"Altunrende","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G\u00fclsan","family":"Sucak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mutlu","family":"Arat","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"T\u00fclay","family":"\u00d6z\u00e7elik","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevgi Kalayo\u011flu","family":"Be\u015f\u0131\u015f\u0131k","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sevda \u00d6zt\u00fcrk","family":"Erden","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3286-2652","authenticated-orcid":false,"given":"Murat","family":"K\u00fcrt\u00fcnc\u00fc","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.msard.2025.106542_bib0002","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1111\/ene.14324","article-title":"Aggressive multiple sclerosis: a single-centre, real-world treatment experience with autologous haematopoietic stem cell transplantation and alemtuzumab","volume":"27","author":"Boffa","year":"2020","journal-title":"Eur. J. Neurol."},{"key":"10.1016\/j.msard.2025.106542_bib0003","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105414","article-title":"Benefits of aHSCT over alemtuzumab in patients with multiple sclerosis besides disability and relapses: sustained improvement in cognition and quality of life","volume":"82","author":"Braun","year":"2024","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106542_bib0004","doi-asserted-by":"crossref","first-page":"1213","DOI":"10.1007\/s10072-017-2933-6","article-title":"Autologous hematopoietic stem cell transplantation in relapsing-remitting multiple sclerosis: comparison with secondary progressive multiple sclerosis","volume":"38","author":"Casanova","year":"2017","journal-title":"Neurol. Sci0"},{"key":"10.1016\/j.msard.2025.106542_bib0005","doi-asserted-by":"crossref","first-page":"1117","DOI":"10.1212\/WNL.0000000000004354","article-title":"Alemtuzumab CARE-MS II 5-year follow-up: efficacy and safety findings","volume":"89","author":"Coles","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106542_bib0006","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.msard.2019.01.039","article-title":"Highly active multiple sclerosis: an update","volume":"30","author":"D\u00edaz","year":"2019","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106542_bib0007","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.1002\/acn3.51366","article-title":"aHSCT is superior to alemtuzumab in maintaining NEDA and improving cognition in multiple sclerosis","volume":"8","author":"H\u00e4u\u00dfler","year":"2021","journal-title":"Ann. Clin. Transl. Neurol."},{"key":"10.1016\/j.msard.2025.106542_bib0008","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1177\/1352458510364538","article-title":"High-dose immunoablation with autologous haematopoietic stem cell transplantation in aggressive multiple sclerosis: a single centre 10-year experience","volume":"16","author":"Krasulov\u00e1","year":"2010","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106542_bib0009","doi-asserted-by":"crossref","first-page":"981","DOI":"10.1212\/WNL.0000000000001329","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a phase II trial","volume":"84","author":"Mancardi","year":"2015","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106542_bib0010","doi-asserted-by":"crossref","first-page":"140","DOI":"10.1038\/s41582-024-01050-x","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis and neuromyelitis optica spectrum disorder \u2014 Recommendations from ECTRIMS and the EBMT","volume":"21","author":"Muraro","year":"2025","journal-title":"Nat. Rev. Neurol."},{"issue":"7","key":"10.1016\/j.msard.2025.106542_bib23","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1038\/nrneurol.2017.81","article-title":"Autologous haematopoietic stem cell transplantation for treatment of multiple sclerosis","volume":"13","author":"Muraro","year":"2017","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.msard.2025.106542_bib0011","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1001\/jamaneurol.2016.5867","article-title":"Long-term outcomes after autologous hematopoietic stem cell transplantation for multiple sclerosis","volume":"74","author":"Muraro","year":"2017","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.msard.2025.106542_bib0012","doi-asserted-by":"crossref","DOI":"10.1002\/ana.27247","article-title":"Effectiveness of autologous hematopoietic stem cell transplantation versus Alemtuzumab and Ocrelizumab in relapsing multiple sclerosis: a single center cohort study","author":"Muraro","year":"2025","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.msard.2025.106542_bib0013","doi-asserted-by":"crossref","first-page":"842","DOI":"10.1212\/WNL.0000000000003660","article-title":"High-dose immunosuppressive therapy and autologous HCT for relapsing-remitting MS","volume":"88","author":"Nash","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106542_bib0014","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1212\/WNL.0000000000005345","article-title":"Comprehensive systematic review summary: disease-modifying therapies for adults with multiple sclerosis: report of the Guideline Development, Dissemination, and Implementation Subcommittee of the American Academy of Neurology","volume":"90","author":"Rae-Grant","year":"2018","journal-title":"Neurology"},{"issue":"5","key":"10.1016\/j.msard.2025.106542_bib22","doi-asserted-by":"crossref","first-page":"1711","DOI":"10.1093\/brain\/awac064","article-title":"Alemtuzumab-induced immune phenotype and repertoire changes: implications for secondary autoimmunity","volume":"145","author":"Ruck","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.msard.2025.106542_bib0015","doi-asserted-by":"crossref","first-page":"283","DOI":"10.1038\/s41409-019-0684-0","volume":"55","author":"Sharrack","year":"2020","journal-title":"Bone Marrow Transplant."},{"key":"10.1016\/j.msard.2025.106542_bib0016","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1136\/jnnp-2023-331864","article-title":"Haematopoietic stem cell transplantation for treatment of relapsing-remitting multiple sclerosis in Sweden: an observational cohort study","volume":"95","author":"Silfverberg","year":"2024","journal-title":"J. Neurol. Neurosurg. Psychiatry"},{"key":"10.1016\/j.msard.2025.106542_bib0017","doi-asserted-by":"crossref","first-page":"201","DOI":"10.1177\/1352458516645670","article-title":"NEDA status in highly active MS can be more easily obtained with autologous hematopoietic stem cell transplantation than other drugs","volume":"23","author":"Sormani","year":"2017","journal-title":"Mult. Scler."},{"key":"10.1016\/j.msard.2025.106542_bib0018","doi-asserted-by":"crossref","first-page":"2115","DOI":"10.1212\/WNL.0000000000003987","article-title":"Autologous hematopoietic stem cell transplantation in multiple sclerosis: a meta-analysis","volume":"88","author":"Sormani","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.msard.2025.106542_bib0019","doi-asserted-by":"crossref","first-page":"3343","DOI":"10.1007\/s00415-020-09983-1","article-title":"Long-term efficacy and safety of alemtuzumab in patients with RRMS: 12-year follow-up of CAMMS223","volume":"267","author":"Steingo","year":"2020","journal-title":"J. Neurol."},{"key":"10.1016\/j.msard.2025.106542_bib0020","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2023.105096","article-title":"Autologous hematopoietic stem cell transplantation is superior to alemtuzumab in patients with highly active relapsing multiple sclerosis and severe disability","volume":"80","author":"Vaisvilas","year":"2023","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.msard.2025.106542_bib0021","doi-asserted-by":"crossref","first-page":"189","DOI":"10.1136\/jnnp-2020-323992","article-title":"Autologous haematopoietic stem cell transplantation compared with alemtuzumab for relapsing-remitting multiple sclerosis: an observational study","volume":"92","author":"Zhukovsky","year":"2021","journal-title":"J. Neurol. Neurosurg. Psychiatry"}],"container-title":["Multiple Sclerosis and Related Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002846?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2211034825002846?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,7,31]],"date-time":"2025-07-31T23:10:51Z","timestamp":1754003451000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2211034825002846"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,8]]},"references-count":22,"alternative-id":["S2211034825002846"],"URL":"https:\/\/doi.org\/10.1016\/j.msard.2025.106542","relation":{},"ISSN":["2211-0348"],"issn-type":[{"value":"2211-0348","type":"print"}],"subject":[],"published":{"date-parts":[[2025,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Comparative analysis of five-year clinical outcomes of autologous hematopoietic stem cell transplantation and alemtuzumab in multiple sclerosis patients","name":"articletitle","label":"Article Title"},{"value":"Multiple Sclerosis and Related Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.msard.2025.106542","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"106542"}}